We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.
Hamilton, Bermuda, June 20, 2024 (GLOBE NEWSWIRE) -- Independent review discusses evidence supporting the use of betahistine to alleviate residual dizziness following physical repositioning...
Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- Achieved significant improvement in handling and transport stability of RNA nanoparticlesPursuing partnering opportunities with AM-125 legacy...
Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing...
Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications...
Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journal Study met primary...
Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDTRNA delivery business progressing with new collaborations, potential new...
Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA...
HAMILTON, BERMUDA, March 25, 2024 (GLOBE NEWSWIRE) -- Univercells to test proprietary mRNA vaccine delivered with Altamira’s SemaPhore™ nanoparticlesTargeting safer and accessible mRNA vaccines...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.11 | 9.90990990991 | 1.11 | 1.3 | 1.11 | 90674 | 1.22345133 | CS |
4 | -0.17 | -12.2302158273 | 1.39 | 1.44 | 1.0501 | 78251 | 1.20506348 | CS |
12 | -0.58 | -32.2222222222 | 1.8 | 2.25 | 1.0501 | 759071 | 1.66604759 | CS |
26 | -2 | -62.1118012422 | 3.22 | 3.49 | 1.0501 | 948321 | 2.08170034 | CS |
52 | -8.06 | -86.8534482759 | 9.28 | 17.2 | 1.0501 | 4583539 | 6.57628666 | CS |
156 | -1170.78 | -99.8959044369 | 1172 | 1548 | 1.0501 | 2569429 | 186.8230784 | CS |
260 | -1170.78 | -99.8959044369 | 1172 | 1548 | 1.0501 | 2569429 | 186.8230784 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions